GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:0071496113 | Thyroid | PTC | cellular response to external stimulus | 158/5968 | 320/18723 | 4.12e-11 | 1.47e-09 | 158 |
GO:000726519 | Thyroid | PTC | Ras protein signal transduction | 162/5968 | 337/18723 | 3.16e-10 | 1.02e-08 | 162 |
GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
GO:0031668113 | Thyroid | PTC | cellular response to extracellular stimulus | 120/5968 | 246/18723 | 2.13e-08 | 4.91e-07 | 120 |
GO:003052228 | Thyroid | PTC | intracellular receptor signaling pathway | 126/5968 | 265/18723 | 6.31e-08 | 1.31e-06 | 126 |
GO:0031669112 | Thyroid | PTC | cellular response to nutrient levels | 106/5968 | 215/18723 | 6.96e-08 | 1.44e-06 | 106 |
GO:19019908 | Thyroid | PTC | regulation of mitotic cell cycle phase transition | 138/5968 | 299/18723 | 1.44e-07 | 2.78e-06 | 138 |
GO:0030518111 | Thyroid | PTC | intracellular steroid hormone receptor signaling pathway | 63/5968 | 116/18723 | 4.53e-07 | 7.41e-06 | 63 |
GO:0031667113 | Thyroid | PTC | response to nutrient levels | 201/5968 | 474/18723 | 7.00e-07 | 1.10e-05 | 201 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:00000829 | Thyroid | PTC | G1/S transition of mitotic cell cycle | 102/5968 | 214/18723 | 9.48e-07 | 1.43e-05 | 102 |
GO:0071383112 | Thyroid | PTC | cellular response to steroid hormone stimulus | 98/5968 | 204/18723 | 9.83e-07 | 1.47e-05 | 98 |
GO:00448439 | Thyroid | PTC | cell cycle G1/S phase transition | 112/5968 | 241/18723 | 1.37e-06 | 1.96e-05 | 112 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:19019878 | Thyroid | PTC | regulation of cell cycle phase transition | 167/5968 | 390/18723 | 2.97e-06 | 3.87e-05 | 167 |
GO:0001667112 | Thyroid | PTC | ameboidal-type cell migration | 198/5968 | 475/18723 | 3.36e-06 | 4.34e-05 | 198 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KANK2 | SNV | Missense_Mutation | rs766622487 | c.739G>A | p.Glu247Lys | p.E247K | Q63ZY3 | protein_coding | deleterious(0) | benign(0.177) | TCGA-34-5240-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
KANK2 | SNV | Missense_Mutation | | c.680N>T | p.Thr227Ile | p.T227I | Q63ZY3 | protein_coding | tolerated(0.09) | benign(0.28) | TCGA-37-4133-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | | c.1435N>G | p.Pro479Ala | p.P479A | Q63ZY3 | protein_coding | tolerated(0.75) | benign(0.164) | TCGA-43-5668-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Other, specify in notesMAGE3-AS15-NSC-003 | clinical | PD |
KANK2 | SNV | Missense_Mutation | novel | c.1757N>T | p.Ser586Leu | p.S586L | Q63ZY3 | protein_coding | deleterious(0.03) | benign(0.037) | TCGA-43-A475-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
KANK2 | SNV | Missense_Mutation | novel | c.484G>T | p.Val162Leu | p.V162L | Q63ZY3 | protein_coding | tolerated(0.42) | benign(0.388) | TCGA-63-A5MJ-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | vinorelbine | SD |
KANK2 | SNV | Missense_Mutation | | c.1852G>A | p.Ala618Thr | p.A618T | Q63ZY3 | protein_coding | tolerated(0.12) | benign(0.116) | TCGA-63-A5MM-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
KANK2 | SNV | Missense_Mutation | novel | c.2248N>T | p.Ala750Ser | p.A750S | Q63ZY3 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-66-2727-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | | c.2239N>C | p.Gly747Arg | p.G747R | Q63ZY3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-66-2756-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | novel | c.1328N>C | p.Ser443Thr | p.S443T | Q63ZY3 | protein_coding | tolerated(0.59) | benign(0) | TCGA-85-8664-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
KANK2 | SNV | Missense_Mutation | | c.1051N>T | p.Ala351Ser | p.A351S | Q63ZY3 | protein_coding | tolerated(0.13) | possibly_damaging(0.839) | TCGA-85-A4CN-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Targeted Molecular therapy | erlotinib | SD |